{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-034729","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.634164+00:00","generated_at":"2026-05-31T06:37:23.079033+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Matinas BioPharma effects 1:50 reverse stock split; trading halted on NYSE American, risk of delisting","bullets":["Effective Aug 30, 2024, Matinas executed a 1:50 reverse stock split and reduced authorized shares from 500M to 250M.","Trading of MTNB halted on NYSE American on Aug 27 due to low price; expects to resume split-adjusted on Sep 3 subject to exchange approval.","If post-split share price fails to meet NYSE American requirements, exchange could suspend trading or delist the stock.","No fractional shares issued; stockholders with fractional entitlements were rounded up to the next whole share.","Reverse split approved by stockholders on Nov 1, 2023; Board authorized filing on Aug 20, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-034729","json":"https://secwatch.observer/filing/0001493152-24-034729.json","markdown":"https://secwatch.observer/filing/0001493152-24-034729.md","text":"https://secwatch.observer/filing/0001493152-24-034729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/0001493152-24-034729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:37:23.079033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}